Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Linde PLC (LIN) vs Novavax Inc (NVAX) Price & Performance

Novavax IncTrade

Price performance (Past 24H)

Key statistics

Linde PLC vs Novavax Inc — how do they compare? Linde PLC trades at $489.06 (market cap $227.01B), while Novavax Inc trades at $7.96 (market cap $1.30B). The key difference: Linde PLC is far larger — about 174.6× Novavax Inc's market cap, and Linde PLC pays a 1.3% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

LINNVAX
Market Cap
$227.01B$1.30B
Sector
Basic MaterialsHealth
52-Week High
$546.64$11.19
52-Week Low
$389.38$6.22
Enterprise Value
$250.13B$879.40M
Dividend Yield
1.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Linde PLC

Linde (LIN) trades at $490.53, up 0.11% on the day, with a bearish technical signal despite strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.50 surpassing expectations. Revenue grew to $34.0B in 2025, with a net income margin of 20.43%. Analysts maintain a strong buy consensus with a $553.60 price target, highlighting robust profitability and dividend growth.

Outlook remains positive due to earnings momentum and sustainability leadership, but risks include elevated valuation multiples and rising debt-to-asset ratio. The stock offers steady income with a $1.60 dividend, yet technical weakness near support at $489 warrants caution for near-term volatility.

Novavax Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Linde PLC

Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.

Read more on LIN

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX